Bevacizumab in non-small-cell lung cancer: A review

Expert Review of Anticancer Therapy

Volumn 11, Issue 8, 2011, Pages 1163-1179

  Planchard, David ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

AVAiL; bevacizumab; ECOG 4599; non small cell lung cancer; VEGF

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; INTEDANIB; MOTESANIB; NAVELBINE; OMBRABULIN; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; THALIDOMIDE; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; XL 647;

ANEMIA; ARTERY THROMBOSIS; ASTHENIA; ASYMPTOMATIC DISEASE; BLEEDING; BRAIN METASTASIS; BRAIN RADIATION; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM HEMORRHAGE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HEMOPTYSIS; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROSURGERY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIOSURGERY; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 80052315962     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.80     Document Type: Review

References (89)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
3. Scagliotti G, Brodowicz T, Shepherd FA et al. Treatment-by-histology interaction analyses in three Phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J. Thorac. Oncol. 6(1), 64-70 (2011).
4. Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3), 353-364 (1996).
6. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 25(4), 581-611 (2004).
7. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2(10), 727-739 (2002).
8. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005).
9. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65(3), 671-680 (2005).
10. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug. Discov. 3(5), 391-400 (2004).
11. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18(1), 4-25 (1997).
12. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell. Res. 312(5), 549-560 (2006).
13. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA. 93(25), 14765-14770 (1996).
14. Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88(12), 1979-1986 (2003).
15. Kerbel RS. Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science 312(5777), 1171-1175 (2006).
16. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19(3), 843-850 (2001).
17. Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 288(1), 371-378 (1999).
18. Verheul HM, Lolkema MP, Qian DZ et al. Platelets take up the monoclonal antibody bevacizumab. Clin. Cancer. Res. 13(18 Pt 1), 5341-5347 (2007).
19. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother. Pharmacol. 62(5), 779-786 (2008).
20. Gaudreault J, Bruno R, Kabbinavar F, Sing A, Johnson DH, Lu J. Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing. J. Clin. Oncol. 22(14 Suppl.) (2004) (Abstract 3041).
21. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184-2191 (2004).
22. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol. 27(8), 1227-1234 (2009).
23. Lilenbaum R, Raez L, Tseng J, Seigel L, Davila E. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J. Thorac. Oncol. 3(5), 511-515 (2008).
24. Patel JD, Hensing TA, Rademaker A et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 27(20), 3284-3289 (2009).
25. William WN Jr, Kies MS, Fossella FV et al. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer 116(10), 2401-2408 (2010).
26. Areses Manrique MC, Vazquez Estévez S, Gracia JM et al. A galician lung cancer group Phase II study of bevacizumab, cisplatin and vinorelbine in chemo-naive patients with non-squamous non small cell lung cancer (NSCLC) Ann. Oncol. 21(8 Suppl.) (2010) (Abstract 432P).
27. Reynolds C, Barrera D, Jotte R et al. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J. Thorac. Oncol. 4(12), 1537-1543 (2009).
28. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006).
29. Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised Phase III trial (AVAiL). Ann. Oncol. 21(9), 1804-1809 (2010).
30. Barlesi F, Pazzola A, Gorbunova V et al. Maintenance bevacizumab (BV) with or without pemetrexed (PEM) following first-line BV-cipsplatin-PEM in patients with advanced non-squamous non-small cell ung cancer: Preliminary safety data from AVAPERL 1 (MO22089) Ann. Oncol. 21(8 Suppl.) (2010) (Abstract 430P).
31. Patel JD, Bonomi P, Socinski MA et al. Treatment rationale and study design for the pointbreak study: A randomized, open-label Phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/ bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin. Lung Cancer 10(4), 252-256 (2009).
32. Soria J, Mauguen A, Reck M et al. Meta-analysis of randomized Phase II/III trials adding bevacizumab to platin-based chemotherapy as 1ST-line treatment in patients with advanced non-small cell lung cancer. Ann. Oncol. 21(8 Suppl.) (2010) (Abstract 437P).
33. Crinó L, Dansin E, Garrido P et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): A Phase 4 study. Lancet Oncol. 11(8), 733-740 (2010).
34. Lynch T, Brahmer J, Fischbach N et al. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS) J. Clin. Oncol. 26, 8077 (2008).
35. Wozniak AJ, Garst J, Jahanzeb M et al. Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS). J. Clin. Oncol. 28(15 Suppl.) (2010) (Abstract 7618).
36. Tabernero J. The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 5(3), 203-220 (2007).
37. Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: Signaling three-dimensional tumor growth. J. Investig. Dermatol. Symp. Proc. 5(1), 24-33 (2000).
38. Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 9(4), 1546-1556 (2003).
39. De Luca A, Carotenuto A, Rachiglio A et al. The role of the EGFR signaling in tumor microenvironment. J. Cell. Physiol. 214(3), 559-567 (2008).
40. Hirata A, Ogawa S, Kometani T et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62(9), 2554-2560 (2002).
41. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151(6), 1523-1530 (1997).
42. Bianco R, Garofalo S, Rosa R et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br. J. Cancer. 98(5), 923-930 (2008).
43. Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res. 61(13), 5090-5101 (2001).
44. Faoro L, Cohen E, Govindan R et al. Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26s (2008) (Abstract 19130).
45. Dingemans AM, de Langen AJ, van den Boogaart V et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: A Phase II study including molecular imaging. Ann. Oncol. 22(3), 559-566 (2011).
46. Gandara D, Kim ES, Herbst RS et al. S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG Phase II study. J. Clin. Oncol. 27(15 Suppl.) (2009) (Abstract 8015).
47. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23(11), 2544-2555 (2005).
48. Salmon S, Chen H, Chen S et al. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J. Thorac. Oncol. 4(6), 689-696 (2009).
49. Herbst RS, O'Neill VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol. 25(30), 4743-4750 (2007).
50. Hainsworth J, Herbst R, Lin M, O'Connor P. A Phase III, multicenter, placebo-controlled, double-blind, randomized, clinical trial to evaluate the efficacy of bevacizumab (Avastin®) in combination with erlotinib (Tarceva®) compared with erlotinib alone for treatment of advanced non-small cell lung cancer (NSCLC) after failure of standard first line chemotherapy (b). J. Thorac. Oncol. 3S(302) (2008).
51. Miller A, O'Connor P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27(18 Suppl.) (2009) (Abstract LBA8002).
52. Kabbinavar FF, Miller VA, Johnson BE, O'Connor PG, Soh C. Overall survival (OS) in ATLAS, a Phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 28(15 Suppl.) (2010) (Abstract 7526).
53. Adjei AA, Mandrekar SJ, Dy GK et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J. Clin. Oncol. 28(4), 614-619 (2010).
54. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst. 99(16), 1232-1239 (2007).
55. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 300(19), 2277-2285 (2008).
56. Novotny W, Holmgren E, Griffing S. Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage (PH) in patients with advanced NSCLC receiving bevacizumab (BV). Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 1318).
57. Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J. Clin. Oncol. 26(1), 60-65 (2008).
58. Leighl NB, Zatloukal P, Mezger J et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the Phase III BO17704 study (AVAiL). J. Thorac. Oncol. 5(12), 1970-1976 (2010).
59. Garrido P, Thatcher N, Crino L et al. Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390). Euro. J. Cancer Suppl. 7(2), 557 (2009).
60. Sandler A, Yi J, Dahlberg S et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J. Thorac. Oncol. 5(9), 1416-1423 (2010).
61. Brahmer J, Spigel D, Garst JL, Jahanzeb M, Vidaver RM, Beatty S. The impact of tumor histology effectiveness in bevacizumab (BV) treated patients with advanced non-small cell lung cancer: Results from ARIES, a BV obvervational cohort study Ann. Oncol. 21(8 Suppl.) (2010) (Abstract 426P).
62. Fischbach NA, Wozniak A, Kumar P et al. Clinical outcomes by sex in non-small cell lung cancer patients: Preliminary results from ARIES, a bevacizumab observational cohort study Ann. Oncol. 21(8 Suppl.) (2010) (Abstract 425P).
63. Brahmer JR, Dahlberg SE, Gray RJ et al. Sex differences in outcome with bevacizumab therapy: Analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J. Thorac. Oncol. 6(1), 103-108 (2011).
64. Sandler AB, Schiller JH, Gray R et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J. Clin. Oncol. 27(9), 1405-1412 (2009).
65. Griesinger F, Bearz A, Eberhardt W et al. Safety of first-line bevacizumab based therapy in the SAiL (MO19390) trial: Central tumor location and hypertension in patients with advanced non-small cell lung cancer. Ann. Oncol. 21(8 Suppl.) (2010) (Abstract 429P).
66. Kumar P, Fischbach NA, Brahmer JR et al. Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS). J. Clin. Oncol. 28(15 Suppl.) (2010) (Abstract 7619).
67. Socinski MA, Langer CJ, Huang JE et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J. Clin. Oncol. 27(31), 5255-5261 (2009).
68. Archer V, Reck M, Sandler AB et al. Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. J. Clin. Oncol. 26(20 Suppl.) (2008) (Abstract 8114).
69. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin. Cancer Res. 16(1), 269-278 (2010).
70. Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. 65(4), 1294-1305 (2005).
71. Laskin J, Hirsh V, Cheng AC, Mezger J, Dansin E. Final safety data from patients who received maintenance bevacizumab in the MO19390 (SAiL) trial: First-line bevacizumab plus chemotherapy in advanced or recurrent non-small cell lung cancer. Ann. Oncol. 21(8 Suppl.) (2010) (Abstract 428P).
72. Nishio M, Horai T, Kunitoh H, Ichinose Y, Nishiwaki Y, Hida T. Randomized, open-label, multicenter Phase II sutdy of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrentnonsquamous non-small cell lung cancer (NSCLC): JO19907. J. Clin. Oncol. 27 (2009) (Abstract 8036).
73. Spigel DR, Hainsworth JD, Yardley DA et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J. Clin. Oncol. 28(1), 43-48 (2010).
74. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group Study. Clin. Cancer Res. 14(5), 1407-1412 (2008).
75. Bernaards C, Hegde P, Chen D et al. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of Phase III studies. J. Clin. Oncol. 28(15 Suppl.) (2010 ) (Abstract 10519).
76. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J. Clin. Oncol. 28(6), 949-954 (2010).
77. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26(28), 4672-4678 (2008).
78. Baar J, Silverman P, Lyons J et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: Impact on angiogenic biomarkers. Clin. Cancer Res. 15(10), 3583-3590 (2009).
79. Zhu AX, Meyerhardt JA, Blaszkowsky LS et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: A Phase 2 study. Lancet Oncol. 11(1), 48-54 (2010).
80. Rizvi NA, Rusch V, Zhao B et al. Single agent bevacizumab and bevacizumab in combination with docetaxel and cisplatin as induction therapy for resectable IB-IIIA non-small cell lung cancer. J. Clin. Oncol. 25(18 Suppl.) (2007).
81. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
82. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon a-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007).
83. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009).
84. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
85. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
86. Altorki N, Lane ME, Bauer T et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J. Clin. Oncol. 28(19), 3131-3137 (2010).
87. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: A Phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J. Clin. Oncol. 27(30), 4966-4972 (2009).
88. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28(20), 3239-3247 (2010).
89. Shaked Y, Henke E, Roodhart JM et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 14(3), 263-273 (2008).